Lianhuan Pharmaceutical: The board of directors approved a credit limit application of up to 271 million yuan for its subsidiary.

Lianhuan Pharmaceutical announced that the company's ninth board of directors held its twenty-sixth temporary meeting and approved the following: its subsidiary Sichuan Longyi Pharmaceutical Co., Ltd. intends to apply to the bank for a total credit facility not exceeding RMB 271 million, effective from the date of approval by the board of directors until the date of the 2026 annual general meeting of shareholders; the controlling subsidiary Lianhuan Medical Technology Co., Ltd. intends to apply for a loan of RMB 10 million from the related party Jiangsu Lianhuan Health Industry Management Development Co., Ltd., with a term not exceeding 3 months, an annual interest rate of 2.5%, and a repayment of principal and interest in one lump sum upon maturity.